Company news
MeiraGTx Holdings plc news in 2020
MeiraGTx Holdings plc's news releases, calls and decks from 2020, newest first.
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
December 15, 2020
MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
November 29, 2020
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 22, 2020
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
November 18, 2020
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
November 17, 2020
MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
November 12, 2020
MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
November 9, 2020
MeiraGTx Reports Third Quarter 2020 Financial Results
November 4, 2020
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting
October 27, 2020
MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)
October 2, 2020
MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference
September 27, 2020
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
September 21, 2020
MeiraGTx Reports Second Quarter 2020 Financial Results
August 5, 2020
MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer
August 4, 2020
MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients
July 16, 2020
MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders
May 25, 2020
MeiraGTx Reports First Quarter 2020 Financial Results
May 6, 2020
MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference
May 5, 2020
MeiraGTx Reports Full Year 2019 Financial Results
March 10, 2020
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
March 1, 2020
MeiraGTx to Present at Upcoming Investor Conferences
February 23, 2020